Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor.
Since HHV-6 reactivation after transplant has been reported to increase the risk of CMV infection, we tested this hypothesis in the HLA-haploidentical hematopoietic stem cell transplantation setting.



From February 2011 to October 2015, 75 patients received hematopoietic stem cell transplantation using a T-cell replete graft from a HLA-haploidentical donor at our Institution.



Interestingly, 87% of HHV-6 reactivations were followed by a CMV reactivation, at a median of 15days between the two viruses. Incidence of CMV reactivation was 14.5-fold higher in those patients with prior HHV-6 reactivation vs. those without it (p-value<0.001).



The present results suggest that HHV-6 can be considered as a predicting indicator of cellular immunosuppression preceding the onset of CMV infection.
Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Roberto
R
Crocchiolo
Biostatistics Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Laura
L
Giordano
Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Andrea
A
Rimondo
Molecular Biology Section, Clinical Investigation Laboratory, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Muriel
M
Bologna
Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Barbara
B
Sarina
Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Lucio
L
Morabito
Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Stefania
S
Bramanti
Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano 20089, Italy.
Luca
L
Castagna
Molecular Biology Section, Clinical Investigation Laboratory, Istituto Clinico Humanitas, Rozzano 20089, Italy. Electronic address: rossana.mineri@humanitas.it.
Rossana
R
Mineri
D003587:Cytomegalovirus / Q000235:genetics / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D015654:Herpesvirus 6, Human / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy; D015994:Incidence; D008297:Male; D008875:Middle Aged; D019349:Roseolovirus Infections / Q000150:complications / Q000821:virology; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000009:adverse effects; D014775:Virus Activation; D014779:Virus Replication
D004279:DNA, Viral
CMV; HHV-6; Haploidentical HSCT; T-cell replete; Viral replication